Compritol ® -based solid lipid nanoparticles of desvenlafaxine prepared by ultrasonication-assisted hot-melt encapsulation to modify its release

Desvenlafaxine (DES) in conventional dosage forms shows initial burst release after oral administration, leading to exaggeration of its side effects. These side effects can be overcome by a sustained-release dosage form using the chemically inert, low-melting-point lipid Compritol 888 ATO, as it red...

Full description

Saved in:
Bibliographic Details
Published in:Nanomedicine (London, England) England), 2024, Vol.19 (11), p.965-978
Main Authors: Rao, Huma, Rao, Iqra, Ahmad, Saeed, Madni, Asadullah, Ahmad, Imtiaz
Format: Article
Language:English
Subjects:
Antidepressive Agents - chemistry
Delayed-Action Preparations - chemistry
Desvenlafaxine Succinate - chemistry
Drug Carriers - chemistry
Drug Compounding - methods
Drug Liberation
Fatty Acids - chemistry
Humans
Lipids - chemistry
Nanoparticles - chemistry
Particle Size
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Desvenlafaxine (DES) in conventional dosage forms shows initial burst release after oral administration, leading to exaggeration of its side effects. These side effects can be overcome by a sustained-release dosage form using the chemically inert, low-melting-point lipid Compritol 888 ATO, as it reduces initial burst release. The potential of DES-loaded solid lipid nanoparticles (DES-SLNs) synthesized by ultrasonication-assisted hot-melt encapsulation to modify the release of DES was investigated. The entrapment efficiency of DES-SLNs was 65.90% with the release profile showing a sustained-release behavior achieving 81% cumulative release within 16 h without initial burst release. DES-SLNs are a potential carrier for sustained release of water-soluble antidepressant drugs such as DES.
ISSN:1743-5889
1748-6963
1748-6963
DOI:10.2217/nnm-2023-0229